Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure

Inclusion Criteria: * Male or female \>18 years of age; Women of non-child-bearing potential must have a documentation of surgical sterilization (hysterectomy and/or bilateral oophorectomy) OR must have experienced menopause (no menses for \>12 months). Women of child bearing potential must have a negative pregnancy test, AND must use highly effective methods of contraception during treatment with IP plus 5 days after the end of study drug administration. * Hospitalized for AHF; AHF is defined as including all of the followings measured at any time between presentation (including the emergency department) and the end of screening: 1. Dyspnea at rest or with minimal exertion 2. Signs of congestion, such as edema, rales, and/or congestion on chest radiograph 3. BNP ≥350 pg/mL or NT-proBNP ≥1,400 pg/mL (for patients with AF: BNP≥500 pg/mL or NT-proBNP ≥2,000 pg/mL) 4. Treated with loop diuretics at screening * Able to be randomized within 24 hours from presentation to the hospital * Able and willing to provide freely given written informed consent * eGFR (CKD-EPI) ≥30 ml/min/1.73m2 between presentation and randomization Exclusion Criteria: * Diabetes Mellitus Type I * Dyspnea primarily due to non-cardiac causes * Cardiogenic shock * Acute coronary syndrome within 30 days prior to randomization * Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization * Signs of keto-acidosis and/or hyperosmolar hyperglaecemic syndrome (pH\>7.30 and glucose \>15 mmol/L and HCO3\>18 mmol/L) * Pregnant or nursing (lactating) women * Current participation in any interventional study * Inability to follow instructions or comply with follow-up procedures * Any other medical conditions that may put the patient at risk or influence study results in the investigator's opinion, or that the investigator deems unsuitable for the study.